Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
November 24th, 2021
2.8K views
A coherent Raman scattering imaging methodology to visualize and quantify pharmaceutical compounds within the skin is described. This paper describes skin tissue preparation (human and mouse) and topical formulation application, image acquisition to quantify spatiotemporal concentration profiles, and preliminary pharmacokinetic analysis to assess topical drug delivery.
Overview
This article presents a coherent Raman scattering imaging methodology for visualizing and quantifying pharmaceutical compounds in the skin. It details the preparation of skin tissue and the application of topical formulations, along with methods for image acquisition and pharmacokinetic analysis.
Key Study Components
Area of Science
- Pharmaceutical sciences
- Dermatology
- Imaging techniques
Background
- Coherent Raman imaging provides a novel approach to study drug delivery in skin.
- Traditional methods often yield bulk pharmacokinetic data.
- This methodology allows for both bulk and microscale analysis.
- Understanding permeation pathways is crucial for targeted drug delivery.
Purpose of Study
- To develop a reproducible method for quantifying topically-applied drugs.
- To visualize drug permeation pathways in skin tissue.
- To enhance the design of drug products for specific target sites.
Methods Used
- Preparation of human and mouse skin tissue.
- Application of topical formulations.
- Image acquisition for spatiotemporal concentration profiling.
- Preliminary pharmacokinetic analysis of drug delivery.
Main Results
- The methodology allows for accurate quantification of drug products.
- It provides insights into the route of drug permeation.
- Tissue preparation is identified as a critical challenge.
- Visualization of drug pathways aids in targeted drug development.
Conclusions
- Coherent Raman imaging is a promising tool for skin pharmacokinetics.
- This approach can improve the efficacy of topical drug formulations.
- Future studies may focus on refining tissue preparation techniques.
Frequently Asked Questions
What is coherent Raman scattering imaging?
It is a technique used to visualize and quantify pharmaceutical compounds in biological tissues.
Why is tissue preparation important?
Proper tissue preparation ensures accurate imaging and quantification of drug permeation.
What are the challenges of this methodology?
The most significant challenge is achieving sufficiently thin tissue for effective imaging.
How does this methodology improve drug delivery studies?
It provides detailed insights into both bulk and microscale pharmacokinetics.
Can this method be applied to human skin?
Yes, the methodology is applicable to both human and mouse skin tissues.
What are the implications for drug product development?
It allows for the design of drug products targeting specific permeation pathways.
Executive Industry Relevance
Coherent Raman scattering imaging enables microscale quantification of active pharmaceutical ingredients in skin, addressing a critical gap in topical bioavailability assessment. This approach provides mechanistic insights into permeation pathways and compartment-specific drug distribution, supporting rational formulation design and go/no-go decisions in early development. By delivering both bulk and spatial pharmacokinetic data, it enhances predictive confidence in topical bioequivalence evaluations.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by visualizing API localization within skin stratifications such as stratum corneum and sebaceous glands.
- Operational Value: Supports biological de-risking through direct observation of permeation routes and retention in lipid-rich versus lipid-poor compartments.
- Predictive Value: Quantifies time-dependent concentration profiles to inform pharmacokinetic modeling and prioritize formulations with sustained flux.
Screening & Assay Development
- Scientific Value: Generates quantitative, label-free concentration maps of APIs across skin layers, enabling mechanistic screening of formulation effects.
- Operational Value: Delivers reproducible spatiotemporal data through standardized tissue preparation and imaging protocols, reducing variability in comparative studies.
- Scalability Value: Facilitates platform reuse across human and mouse skin models, supporting cross-species extrapolation in preclinical evaluation.
Translational & Preclinical Research
- Translational Value: Bridges discovery and preclinical workflows by providing human-relevant microscale pharmacokinetic data essential for bioequivalence assessment.
- Mechanistic De-risking: Clarifies whether observed flux limitations stem from formulation properties or tissue barriers, informing mitigation strategies.
- Predictive Confidence: Enables estimation of micro- and macroscale bioavailability from compartment-specific accumulation, improving dose prediction accuracy.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early hypothesis testing through lead identification to preclinical validation, particularly for topical and dermal delivery programs requiring mechanistic permeability insights.
- Discovery Biology: Supports pathway clarification by mapping API distribution across anatomical structures like sebaceous glands and adipocytes, enabling target-site alignment.
- Screening: Delivers assay-ready, quantitative outputs via SRS signal linearity with concentration, allowing direct comparison of formulation performance across time points.
- Analytics: Enables non-compartmental analysis of intensity-time profiles to derive Jmax and AUCflux metrics, supporting statistical comparison of experimental conditions.
- Translational Research: Connects to preclinical continuity through human skin applicability, ensuring relevance to regulatory bioavailability and bioequivalence studies.
- Enterprise Reuse: Establishes a standardized, label-free imaging capability applicable across multiple APIs and formulations, reducing redundant method development.
Operational & Enterprise Impact
- Scientific Value: Provides predictive confidence in target engagement by quantifying API accumulation in therapeutically relevant skin compartments.
- Operational Value: Ensures reproducibility through standardized tissue mounting, immobilization, and sequential imaging workflows minimizing artifacts.
- Strategic Value: Improves go/no-go decisions by identifying formulations with sustained permeation, reducing late-stage failure due to inadequate bioavailability.
- Portfolio Impact: Enables risk-adjusted prioritization based on mechanistic permeability data, optimizing capital allocation in topical development programs.
Implementation Considerations
- Requires expertise in coherent Raman imaging, tissue handling, and pharmacokinetic analysis to ensure accurate data interpretation.
- Demands laser scanning microscopy with tunable wavelength and photodiode detection for SRS, along with environmental control for tissue viability.
- Necessitates cross-team standardization of tissue preparation, mounting, and ROI definition to maintain consistency across sites and studies.
- Involves adaptation considerations for varying skin thickness, lipid content, and appendage density between species and anatomical sites.
- Includes practical limitations such as the need for thin tissue sections and potential signal interference from endogenous lipids or melanin.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in CRI studies?
Null hypothesis testing determines whether observed API accumulation in skin strata exceeds background levels, confirming specific localization rather than nonspecific distribution. This statistical validation supports target engagement claims by distinguishing true permeation from artifact. It ensures mechanistic de-risking is based on significant, reproducible signals.
How does independent variable isolation fit the discovery pipeline in topical API quantification?
Isolating variables such as formulation type, dose, or skin region enables attribution of permeation differences to specific factors, supporting structure-activity relationships in early screening. This control is essential when comparing gel versus solution formulations to assess excipient effects on flux. It ensures that observed changes in Jmax or AUC are formulation-driven, not confounded by tissue variability.
What quantitative dependent variable measurements enable mechanistic screening in SRS-based CRI?
The SRS signal intensity, which is linearly proportional to molecular concentration, serves as the dependent variable for quantifying API levels across skin layers over time. These measurements allow derivation of concentration-time profiles and flux metrics such as Jmax and AUC. Such quantitative outputs are necessary for non-compartmental analysis and comparative potency assessment.
Why do replication requirements matter for cross-functional collaboration in CRI workflows?
Replication across tissue sections, time points, and experimental runs ensures that permeation observations are consistent and not due to mounting artifacts or laser drift. This reliability is critical when transferring methods between discovery, preclinical, and translational teams. Standardized replication supports audit readiness and regulatory scrutiny in bioavailability studies.
What statistical analysis capabilities are required before implementing CRI for topical BA/BE assessment?
Capabilities for non-compartmental analysis, comparison of Jmax and AUCflux across conditions, and statistical testing of intensity-time profiles are required to evaluate formulation performance. These analyses enable estimation of micro- and macroscale bioavailability and support bioequivalence conclusions. Implementation depends on access to tools like RStudio and validated scripts for pharmacokinetic modeling.
Chapters in this video
0:04
Introduction
0:56
Preparation of Nude Mouse Ear Skin Tissue
1:46
Preparation of Human Skin Tissue
2:26
Lipid Imaging and Application of Topical Formulation
3:11
Experimental Setup for Drug Quantification and Data Analysis
8:53
Results: Analysis of the Skin for Tissue Movement and Concentration of Drug at Different Timepoints
10:28
Conclusion
